Influenza A virus H5N1 surface glycoproteins (Hemagglutinin and Neuraminidase) (H5N1 HA/NA)

Influenza A H5N1 viral glycoproteins consist of two primary surface proteins: Hemagglutinin (HA) and Neuraminidase (NA). Hemagglutinin is a trimeric glycoprotein responsible for binding the virus to host cell sialic acid receptors and facilitating the fusion of the viral envelope with the endosomal membrane during entry. Neuraminidase is a tetrameric enzyme that cleaves terminal sialic acid residues from glycoproteins and glycolipids, a process essential for the release of newly formed virions from infected cells and preventing viral aggregation. These proteins are the primary targets for the host immune response and the focus of most pharmacological interventions. In the context of H5N1, a highly pathogenic avian influenza strain, these glycoproteins are critical determinants of host range, tissue tropism, and systemic virulence. Current therapeutic strategies primarily target the enzymatic site of Neuraminidase to limit viral spread, while vaccines and experimental monoclonal antibodies aim to neutralize the virus by targeting the globular head or the conserved stem region of Hemagglutinin.

Other names

H5N1 viral envelope proteinsH5 hemagglutininN1 neuraminidaseInfluenza A H5N1 surface antigens

Neuraminidase inhibitors (e.g., Oseltamivir) block the enzymatic activity of NA, preventing the cleavage of sialic acid receptors and trapping progeny virions on the host cell surface. Hemagglutinin inhibitors (e.g., Umifenovir or neutralizing antibodies) prevent viral entry by blocking HA-mediated binding to host cell receptors or inhibiting the pH-dependent conformational change required for membrane fusion.